Hers vs Henry Meds: Big Platform vs Focused Program

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub, our library on GLP-1 programs, subscription telehealth, and the genetics that shape metabolic care. Browse all Peptides & GLP-1 education

This is an independent editorial comparison. PlexusDx has no commercial relationship with Hers or Henry Meds and earns no affiliate compensation from either.

Full head-to-head: PlexusDx vs Henry Meds →

Hers and Henry Meds represent two different flavors of GLP-1 telehealth: one a large consumer-health subscription brand, the other a focused compounding-pharmacy program. This comparison looks at what that difference means in practice and at the genetic factor neither addresses. As of April 2026.

A big-platform brand meets a focused program

Hers is the women's arm of Hims & Hers Health, a large subscription-telehealth platform spanning many condition categories, with weight management one offering among many. Henry Meds is a more narrowly focused telehealth-plus-compounding program. Both evaluate you virtually and dispense branded or compounded GLP-1s through licensed pharmacy pathways, but they arrive at the same category from different scales.

How enrollment and oversight feel

With either brand, you begin at an intake and a provider's review rather than an open purchase, and a prescription follows only on approval. A broad platform like Hers folds weight care into a wider membership and app experience; a specialist like Henry keeps its lens on the metabolic program itself. Provider type and follow-up cadence vary, so read each brand's current model on its own site: Hers and Henry Meds.

Medication menus and formats

Both can prescribe GLP-1 receptor agonists, but the specific products, formats, and dispensing pathways differ between a large multi-category platform and a compounding-focused program. Whether a given compound is offered branded or compounded, and injectable or oral, depends on each brand's current catalog. A larger platform sometimes carries a wider range of adjacent products, while a focused program may go deeper on the specific compounds it does offer. Confirm the exact menu directly, since these lineups change often.

Reading pricing carefully

Pricing here is best treated as a range rather than a fixed quote: across the market as of April 2026, all-in monthly totals commonly span roughly $200 to $700 or more, including program fees, medication, and compounded dispensing where relevant. Hers and Henry Meds each publish their own current numbers; verify both directly before committing.

Identical pharmacology, individual genetics

Neither brand alters the compound class: GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual agonist tirzepatide, supported by STEP (NEJM, 2021), SURMOUNT (NEJM, 2022), and SURMOUNT-OSA (NEJM, 2024). What differs from one person to the next is genetic. Variants in FTO, GLP1R, MC4R, and TCF7L2 chart the metabolic baseline a GLP-1 acts upon — pathway-level context, not a prediction, that neither Hers nor Henry Meds captures.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — Semaglutide Injection at $189/month, Tirzepatide Injection at $289/month, plus Semaglutide Oral and Tirzepatide Oral. The Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights and does not predict response to any specific medication.

Not affiliated: PlexusDx is independent of both Hers and Henry Meds and has no commercial relationship with the companies reviewed here.

Related reading on PlexusDx: GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hers or Henry Meds and has no commercial relationship with the companies reviewed. PlexusDx offers its own Weight Management Protocols, so this piece compares approaches within the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before starting any peptide protocol.

Compare the approach: see the Weight Management Protocols, or start with the Precision Peptide Genetic Test.

Frequently Asked Questions

What is the main difference between Hers and Henry Meds?

Hers is the women's line of a large multi-category subscription-telehealth platform, while Henry Meds is a focused telehealth-plus-compounding program. Both prescribe GLP-1 therapy after a clinical review, but they differ in scale, app experience, and how weight care fits into their broader offering. Read each brand's current model.

Is one program more legitimate than the other?

Both operate with licensed clinicians and pharmacy partners as of April 2026. Legitimacy depends on real clinical evaluation, transparent terms, and state-licensed dispensing rather than brand size. Verify current licensure and program specifics on each brand's own site before making any decision.

Do Hers and Henry Meds cost the same?

Not necessarily. Pricing varies by compound, format, dispensing pathway, and subscription structure, and each brand publishes its own current figures. Treat any number you see secondhand as potentially stale, and confirm live pricing on both sites, since all-in monthly totals in this market vary widely.

Does genetic testing replace choosing a program?

No. The Precision Peptide Genetic Test is upstream context, not a substitute for a program. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that describe your baseline biology and does not predict response, so it complements whichever telehealth program you choose.

More in the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.